Dialysis patients on denosumab (Prolia, Xgeva) had a lower risk for fracture but higher risk for a certain heart event, ...

For dialysis-dependent patients treated for osteoporosis, denosumab is associated with a greater preventive effect on ...

For dialysis-dependent patients treated for osteoporosis, denosumab is associated with a greater preventive effect on ...

FDA committee recommends Amgen's denosumab, for the treatment, but not prevention, of bone loss, while Lilly decides not to submit arzoxifene for regulatory review after 5-year trial. Later this ...

欧盟人用医药产品委员会 (CHMP)对Celltrion的三种候选生物仿制药——Eydenzelt® (aflibercept)、Stoboclo®和Osenvelt® (denosumab)以及Avtozma® (tocilizumab)给出积极意见 ...

In dialysis-dependent patients, those on denosumab for fracture risk had a 36% higher MACE rate than those on bisphosphonates ...

Bio-Thera Solutions Inc. announced that it has partnered with Tabuk Pharmaceutical Manufacturing Company to commercialize BAT2206, ...

Study finds dialysis patients taking denosumab have 36% higher risk for major cardiovascular events compared to those taking oral bisphosphonates.

Celltrion’s denosumab biosimilar demonstrated equivalent efficacy, safety, and immunogenicity compared with the originator in ...

Denosumab biosimilar is under clinical development by Samsung Bioepis and currently in Phase III for Post Menopausal Osteoporosis.

Researchers have found in a observational study that dialysis patients on denosumab (Prolia, Xgeva) had a lower risk for ...